English Version

acquired majority

stakes from



JAQAR Corporate Strategy has exclusively guided Sullab, a distributor of hospital and pharmaceutical diagnostic products, in the sale of majority stake to Meissa Capital, a search fund supported by institutional investors and individuals with extensive experience in investments in the United States, Latin America and Europe.
Sullab was founded in 1982 and is currently a regional leader in supplying equipment as well as providing services for laboratories, hospitals and other healthcare establishments. Their customer base includes clients in the areas of hematology, immunology, biochemistry, microbiology, molecular biology, and scientific research.
Meissa Capital is one of the first search funds to contribute in the Brazilian market. It is supported by expert investors in international management, committed to the long-term sustainability of their businesses.

Success Case: Sullab is a firm of regional success with more than 35 years in the market, having an exceptional track record in its industry. JAQAR’s first challenge in the Sullab project was to provide a solution for the lack of strategic alignment among the partners of the company. Then, we began preparing the company regarding the norms of governance, financial controllership, marketing, and management, looking to attract investors that share the goal of the majority shareholder: long-term sustainability and growth ensuring longevity in their market sector. Following an intense negotiation period, Sullab opted to partner with Meissa Capital, seeing as though the values, culture, and strategy of both institutions were aligned. This way, the strength of Sullab’s sustainability pillars aggregated to Meissa Capital’s capital and international expertise will maximize the possibilities of success for this new partnership.